STING agonists utilize the principle of cGAS-STING-induced type I interferon response and are now commonly used in clinical practice as one of the anti-tumor treatments (Jiang et al., 2020; Wang Y. et al., 2020; Amouzegar et al., 2021). This evidence concerns the gene CGAS and neoplasm.